Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?

NCT00867971 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2009-03-24

No results posted yet for this study

Summary

Recombinant growth hormone is a common therapy in the pediatric population. A number of associated side effects have been described. Several years ago, a case report was published concerning a child that was treated with RGH and developed acute glaucoma. To date no study has evaluated the connection.

Conditions

Interventions

OTHER

Measuring intraoccular pressure

Measurement of intraoccular pressure by tonometry

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00867971 on ClinicalTrials.gov